PowerVision (Belmont, California), a company developing an accommodating, fluid-controlled intraocular lens (IOL) designed to mimic the way a healthy human eye works, said it has closed the first tranche of its Series D funding round, raising $20 million. Existing investors Venrock, Johnson & Johnson Development, Medtronic, Advanced Technology Ventures, Lexington Capital, and Frazier Healthcare Ventures participated in the round. PowerVision says it plans to raise up to an additional $10 million as part of the same financing round.